<DOC>
	<DOCNO>NCT01601613</DOCNO>
	<brief_summary>This trial conduct Asia . The aim investigate efficacy safety activate recombinant human factor VII ( rFVIIa ) achieve haemostasis patient Dengue haemorrhagic fever ( DHF ) .</brief_summary>
	<brief_title>Activated Recombinant Human Factor VII Patients With Dengue Haemorrhagic Fever</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Patients clinical diagnosis Dengue Haemorrhagic Fever ( DHF ) Patients clinical diagnosis DHF Grades II III8 , require standard replacement therapy Patients clinical diagnosis DHF Grade IV Known suspect allergy trial product related product Known hypersensitivity mouse , hamster bovine protein Prior treatment activate recombinant human factor VII</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>